The original success of Sildenafil undeniably revolutionized the medication landscape, but investing in companies primarily reliant on generic versions presents a complex picture. Although early returns were substantial, the expiration of patents and the emergence of discounted alternatives have eroded market share. Therefore, a thorough analysis o